JP2012500090A - 高所病を最小限に抑える及び治療するための装置及び方法 - Google Patents
高所病を最小限に抑える及び治療するための装置及び方法 Download PDFInfo
- Publication number
- JP2012500090A JP2012500090A JP2011523890A JP2011523890A JP2012500090A JP 2012500090 A JP2012500090 A JP 2012500090A JP 2011523890 A JP2011523890 A JP 2011523890A JP 2011523890 A JP2011523890 A JP 2011523890A JP 2012500090 A JP2012500090 A JP 2012500090A
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- handheld device
- reservoir
- nitrogen dioxide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 206010025482 malaise Diseases 0.000 title claims abstract description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 166
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001301 oxygen Substances 0.000 claims abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 210000004072 lung Anatomy 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 239000007789 gas Substances 0.000 claims description 45
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 26
- 239000003570 air Substances 0.000 claims description 25
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000011149 active material Substances 0.000 claims description 10
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002640 oxygen therapy Methods 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 6
- 229940087168 alpha tocopherol Drugs 0.000 claims 3
- 229960000984 tocofersolan Drugs 0.000 claims 3
- 239000002076 α-tocopherol Substances 0.000 claims 3
- 239000002478 γ-tocopherol Substances 0.000 claims 3
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008016 vaporization Effects 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000009792 diffusion process Methods 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 208000035202 High altitude pulmonary edema Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000018875 hypoxemia Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- FXXMDJFRMDVSCF-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hydrate Chemical compound O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O FXXMDJFRMDVSCF-RXSVEWSESA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000034388 Mountain sickness acute Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008702 acute hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 208000018315 acute mountain sickness Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940100563 gas for inhalation Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0666—Nasal cannulas or tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/106—Filters in a path
- A61M16/107—Filters in a path in the inspiratory path
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/03—Gases in liquid phase, e.g. cryogenic liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3613—General characteristics of the apparatus related to heating or cooling by body heat
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
Abstract
【選択図】図2
Description
本願は、米国仮出願番号第61/090,617号(2008年8月21日出願、その全体は参照により本明細書中に組み込まれている。)の優先権の利益を主張する。
本明細書は、高所病を最小限に抑え、かつ治療するための装置及び方法に関する。
典型的に、高地に見られる低酸素環境への曝露は、個人に高所病を発生させ得る。高所病には、比較的軽度なものから重篤なものまで存在し得る。高所病の比較的軽度な形態は、急性高山病であり、これは、限定はされないが、頭痛、息切れ、疲労、悪心、嘔吐又は不眠などの症状に特徴付けられる。高所病の重篤な形態を挙げると、高所肺水腫(HAPE)及び高所脳浮腫(HACE)がある。HAPEは、肺高血圧症、肺毛細血管透過性の亢進、及び低酸素血症などの症状によって特徴付けられる。HACEは、挙動の変化、嗜眠、錯乱及び運動失調に特徴付けられる。
簡潔に、かつ一般的用語で、様々な実施態様が、高所病を最小限に抑え、かつ治療するための方法及び装置に関する。高所とは、海抜2,438.4m(8,000フィート)より上、海抜3,048m(10,000フィート)より上、海抜3,657.6m(12,000フィート)より上、海抜4,267.2m(14,000フィート)より上、海抜4,876.8m(16,000フィート)より上、海抜5,486.4m(18,000フィート)より上、及びそれより高い高度とすることができる。
高高度の位置における環境などの低酸素環境は、肺における部分的な動脈圧を低下させ、結果として、急性の低酸素性肺血管収縮(HPV)及び低酸素血症(動脈血中の溶存酸素濃度の欠乏)を招くおそれがある。HPVは、高い二酸化炭素レベルを伴わない低酸素(低酸素レベル)の存在下で肺動脈が収縮する生理的現象であり、より高い酸素分圧で血流の向きを肺胞へと変える。HPVは、心拍出量の低下、肺水腫及び右室不全を含む深刻な血行動態的事象をもたらし得るが、十分な肺胞の酸素供給を回復することができる場合、元に戻すことができる。
Claims (25)
- 個人が高地にいる場合に、治療量の一酸化窒素を個人の肺に送達することを含む、高所病の治療方法。
- 空気又は酸素富化空気を一酸化窒素とともに送達することを更に含む、請求項1記載の方法。
- 二酸化窒素を抗酸化剤に接触させることによって、一酸化窒素を発生することを更に含む、請求項1記載の方法。
- 前記抗酸化剤が、アスコルビン酸、αトコフェロール又はγトコフェロールである、請求項3記載の方法。
- 四酸化二窒素を気化して二酸化窒素にすること;及び
二酸化窒素を抗酸化剤に接触させることによって、一酸化窒素を発生させること;を更に含む、請求項1記載の方法。 - 前記抗酸化剤が、アスコルビン酸、αトコフェロール又はγトコフェロールである、請求項5記載の方法。
- 前記治療量の一酸化窒素が、少なくとも1ppmである、請求項1記載の方法。
- 前記治療量の一酸化窒素が、手持ち式装置を介して送達される、請求項1記載の方法。
- 一酸化窒素送達のための手持ち式装置であって、
二酸化窒素を含むリザーバ;
該リザーバと連結した変換カートリッジ;及び
該変換カートリッジと連結した患者用インターフェイス;を含み、該患者用インターフェイスに到達するのに先立って、該変換カートリッジが二酸化窒素を一酸化窒素に変換する、前記手持ち式装置。 - 前記リザーバと連通しているポンプを更に含む、請求項9記載の手持ち式装置。
- 前記ポンプが、電池駆動式ポンプである、請求項10記載の手持ち式装置。
- 前記変換カートリッジに付属した加熱素子を更に含む、請求項9記載の手持ち式装置。
- 前記患者用インターフェイスが、マウスピース、鼻カニューレ、フェイスマスク又は完全密封されたフェイスマスクである、請求項9記載の手持ち式装置。
- 前記リザーバが、ガス透過セルである、請求項9記載の手持ち式装置。
- 前記リザーバが、希釈ガスを伴い又は伴わずに圧縮二酸化窒素を含む、請求項9記載の手持ち式装置。
- 前記リザーバが、窒素、空気、酸素富化空気、又は実質的に純粋な酸素を更に含む、請求項9記載の手持ち式装置。
- 前記変換カートリッジが、抗酸化剤の水溶液で飽和された表面活性材料を更に含む、請求項9記載の手持ち式装置。
- 前記表面活性材料が、シリカゲルである、請求項17記載の手持ち式装置。
- 前記抗酸化剤が、アスコルビン酸、αトコフェロール又はγトコフェロールである、請求項17記載の手持ち式装置。
- 前記患者用インターフェイスが、患者の口又は鼻への送達管である、請求項9記載の手持ち式装置。
- 患者の身体に着けるのに適した、請求項20記載の手持ち式装置。
- 二酸化窒素を一酸化窒素に変換するための変換カートリッジであって、
二酸化窒素を一酸化窒素に変換するための抗酸化剤の水溶液で飽和された表面活性材料を含む、第1の端部及び第2の端部を有する本体を含み、該第1の端部は、二酸化窒素、四酸化二窒素又は一酸化窒素の供給源と係合する大きさに設定され、かつ該本体の第2の端部は、患者用インターフェイスと係合可能である、前記変換カートリッジ。 - 患者の身体に着けるのに適した、請求項22記載の変換装置。
- 前記患者用インターフェイスが、患者の口又は鼻への送達管である、請求項23記載の変換装置。
- 在宅酸素療法の代替法であって、
一酸化窒素を発生し、かつ患者に送達するための可搬式装置を提供すること;及び
治療量の一酸化窒素を個人の肺に送達すること;を含む、前記代替法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9061708P | 2008-08-21 | 2008-08-21 | |
US61/090,617 | 2008-08-21 | ||
US12/541,144 US10780241B2 (en) | 2008-08-21 | 2009-08-13 | Devices and methods for minimizing and treating high-altitude sickness |
US12/541,144 | 2009-08-13 | ||
PCT/US2009/053945 WO2010021941A1 (en) | 2008-08-21 | 2009-08-14 | Devices and methods for minimizing and treating high-altitude sickness |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014025275A Division JP5881758B2 (ja) | 2008-08-21 | 2014-02-13 | 高所病を最小限に抑える及び治療するための装置及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012500090A true JP2012500090A (ja) | 2012-01-05 |
JP2012500090A5 JP2012500090A5 (ja) | 2012-09-27 |
Family
ID=41695166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011523890A Pending JP2012500090A (ja) | 2008-08-21 | 2009-08-14 | 高所病を最小限に抑える及び治療するための装置及び方法 |
JP2014025275A Active JP5881758B2 (ja) | 2008-08-21 | 2014-02-13 | 高所病を最小限に抑える及び治療するための装置及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014025275A Active JP5881758B2 (ja) | 2008-08-21 | 2014-02-13 | 高所病を最小限に抑える及び治療するための装置及び方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US10780241B2 (ja) |
EP (1) | EP2326375B1 (ja) |
JP (2) | JP2012500090A (ja) |
AU (1) | AU2009282985B2 (ja) |
CA (1) | CA2734785C (ja) |
WO (1) | WO2010021941A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10780241B2 (en) * | 2008-08-21 | 2020-09-22 | Vero Biotech LLC | Devices and methods for minimizing and treating high-altitude sickness |
US10960168B2 (en) * | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
EP2501427B1 (en) * | 2009-11-20 | 2018-03-21 | Geno LLC | Nitric oxide delivery system |
WO2011137124A1 (en) * | 2010-04-26 | 2011-11-03 | Geno Llc | Delivery of ultra pure nitric oxide (no) |
EP3360557A3 (en) | 2010-12-03 | 2018-11-07 | Geno LLC | Nitric oxide treatments |
JP2014527025A (ja) | 2011-05-27 | 2014-10-09 | ゲノ エルエルシー | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
US10525226B2 (en) * | 2014-05-14 | 2020-01-07 | Mallinckrodt Hospital Products IP Limited | Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient |
CA2965159A1 (en) | 2014-10-20 | 2016-04-28 | Geno Llc | Nitrogen dioxide storage cassette |
EP3302277A4 (en) * | 2015-05-25 | 2019-01-02 | VERO Biotech LLC | Nitric oxide treatment system and method |
JP2019506259A (ja) * | 2015-12-11 | 2019-03-07 | ベロ バイオテック エルエルシー | 線維症に対処するために一酸化窒素を含むガスを投与するための方法及び装置 |
US20170326328A1 (en) * | 2016-05-11 | 2017-11-16 | Joshua Hensley | Peripheral neuropathy breathing device |
US11617847B2 (en) | 2017-01-11 | 2023-04-04 | Model Software Corporation | Methods for minimizing delayed effects of exposure to reduced oxygen partial pressure via administration of supplemental oxygen |
US10532175B1 (en) | 2019-05-23 | 2020-01-14 | Model Software Corporation | Methods for minimizing delayed effects of exposure to reduced oxygen partial pressure via administration of supplemental oxygen |
JP2020510499A (ja) | 2017-02-27 | 2020-04-09 | サード ポール, インコーポレイテッドThird Pole, Inc. | 酸化窒素の移動式生成システムおよび方法 |
JP6704094B2 (ja) | 2017-02-27 | 2020-06-03 | サード ポール, インコーポレイテッドThird Pole, Inc. | 酸化窒素を生成するためのシステムおよび方法 |
MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
WO2018211474A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
US11045620B2 (en) | 2019-05-15 | 2021-06-29 | Third Pole, Inc. | Electrodes for nitric oxide generation |
US11479464B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole Inc | SYSTEMS AND METHODS FOR GENERATING NITRIC OXIDE WITH HUMIDITY CONTROL |
US20210395905A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
WO2023049873A1 (en) | 2021-09-23 | 2023-03-30 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
DE102023203578A1 (de) | 2023-04-19 | 2024-10-24 | Robert Bosch Gesellschaft mit beschränkter Haftung | Wechseleinsatz für ein Mundstück eines Atemanalysegeräts |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158175A (ja) * | 1990-12-05 | 1998-06-16 | General Hospital Corp:The | 気管支収縮を伴う患者を治療する薬剤組成物及びその吸入用装置 |
JP2008510675A (ja) * | 2004-08-18 | 2008-04-10 | ゲノ エルエルシー | 二酸化窒素(no2)の酸化窒素(no)への変換 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2622593A (en) * | 1950-12-12 | 1952-12-23 | Peirano Horacio | Atomizing apparatus |
US3521865A (en) * | 1968-05-20 | 1970-07-28 | Du Pont | Generation of accurately known vapor concentrations by permeation |
US4003240A (en) * | 1975-06-13 | 1977-01-18 | Honeywell Inc. | Calibration device for vaporized liquids |
US4106505A (en) * | 1977-01-17 | 1978-08-15 | Salter Labs., Inc. | Nasal cannula assembly |
FI82147C (fi) * | 1988-10-27 | 1991-01-10 | Vaisala Oy | Kontrollanordning foer fuktmaetare foer faeltbruk. |
US5156334A (en) * | 1990-08-15 | 1992-10-20 | Kimbell Charles L | Gas permeation system |
US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
WO1995007610A1 (en) | 1993-09-13 | 1995-03-23 | Aga Aktiebolag | Method and means for generating nitric oxide |
SE502355C2 (sv) * | 1994-02-17 | 1995-10-09 | Hans Stymne | Sätt jämte anordning för att avge små mängder gas från ett ämne i kondenserad form till omgivningen med kontrollerbar hastighet |
US5491929A (en) * | 1994-10-11 | 1996-02-20 | Speedy Products Co. | Leak-resistant transportation and storage container |
US5692495A (en) * | 1996-04-02 | 1997-12-02 | The Boc Group, Inc. | Method and apparatus for the production of nitric oxide gas mixture |
US5765548A (en) * | 1996-05-07 | 1998-06-16 | Perry; Bryan J. | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine |
EP0973499B1 (en) * | 1997-03-31 | 2003-08-06 | Alza Corporation | Diffusional implantable delivery system |
US6269811B1 (en) * | 1998-11-13 | 2001-08-07 | Respironics, Inc. | Pressure support system with a primary and a secondary gas flow and a method of using same |
JP3331331B2 (ja) * | 1999-06-03 | 2002-10-07 | 松下電器産業株式会社 | 通信端末装置及び過干渉防止方法 |
US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
AU2002336401A1 (en) | 2001-09-05 | 2003-03-18 | Cyterra Corporation | Nitric oxide generation |
US7458373B2 (en) | 2002-01-15 | 2008-12-02 | Philip Morris Usa Inc. | Aerosol generator for drug formulation |
US7399449B1 (en) * | 2002-05-14 | 2008-07-15 | Sandia Corporation | Microfabricated diffusion source |
JP3720032B2 (ja) | 2003-01-21 | 2005-11-24 | 株式会社アプティック | 高気圧式酸素供給装置及びそれに用いるチャンバ |
US7588033B2 (en) * | 2003-06-18 | 2009-09-15 | Breathe Technologies, Inc. | Methods, systems and devices for improving ventilation in a lung area |
US8381729B2 (en) * | 2003-06-18 | 2013-02-26 | Breathe Technologies, Inc. | Methods and devices for minimally invasive respiratory support |
US7618594B2 (en) * | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
EP1788588B1 (en) * | 2004-09-01 | 2015-08-26 | Sumitomo Electric Industries, Ltd. | Soft magnetic material, dust core and method for producing dust core |
US20060096596A1 (en) * | 2004-11-05 | 2006-05-11 | Occhialini James M | Wearable system for positive airway pressure therapy |
US7171963B2 (en) * | 2005-02-09 | 2007-02-06 | Vbox, Incorporated | Product pump for an oxygen concentrator |
US10780241B2 (en) * | 2008-08-21 | 2020-09-22 | Vero Biotech LLC | Devices and methods for minimizing and treating high-altitude sickness |
-
2009
- 2009-08-13 US US12/541,144 patent/US10780241B2/en active Active
- 2009-08-14 JP JP2011523890A patent/JP2012500090A/ja active Pending
- 2009-08-14 EP EP09808646.5A patent/EP2326375B1/en active Active
- 2009-08-14 WO PCT/US2009/053945 patent/WO2010021941A1/en active Application Filing
- 2009-08-14 CA CA2734785A patent/CA2734785C/en active Active
- 2009-08-14 AU AU2009282985A patent/AU2009282985B2/en not_active Ceased
-
2014
- 2014-02-13 JP JP2014025275A patent/JP5881758B2/ja active Active
-
2020
- 2020-09-18 US US17/025,298 patent/US20210100972A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158175A (ja) * | 1990-12-05 | 1998-06-16 | General Hospital Corp:The | 気管支収縮を伴う患者を治療する薬剤組成物及びその吸入用装置 |
JP2008510675A (ja) * | 2004-08-18 | 2008-04-10 | ゲノ エルエルシー | 二酸化窒素(no2)の酸化窒素(no)への変換 |
Also Published As
Publication number | Publication date |
---|---|
US20100043788A1 (en) | 2010-02-25 |
CA2734785C (en) | 2018-03-13 |
JP2014121634A (ja) | 2014-07-03 |
AU2009282985B2 (en) | 2016-02-25 |
WO2010021941A1 (en) | 2010-02-25 |
EP2326375A1 (en) | 2011-06-01 |
CA2734785A1 (en) | 2010-10-25 |
US10780241B2 (en) | 2020-09-22 |
EP2326375A4 (en) | 2012-08-22 |
EP2326375B1 (en) | 2016-10-05 |
US20210100972A1 (en) | 2021-04-08 |
AU2009282985A1 (en) | 2010-02-25 |
JP5881758B2 (ja) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5881758B2 (ja) | 高所病を最小限に抑える及び治療するための装置及び方法 | |
US20220016379A1 (en) | Delivery of high concentration nitric oxide | |
US8646445B2 (en) | Nitric oxide delivery system | |
JP5911475B2 (ja) | 超高純度一酸化窒素(no)の送達 | |
AU2011336358B2 (en) | Nitric oxide treatments | |
US20020192163A1 (en) | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies | |
ES2508090T3 (es) | Dispositivo para el abastecimiento con un gas de un paciente | |
RU196168U1 (ru) | Ксеноновый терапевтический ингаляционный аппарат с обратной связью |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140422 |